Giredestrant shows significant improvement in iDFS in patients with early-stage, HR-positive, HER2-negative breast cancer.

The FDA has approved Myqorzo for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms.

Recommendations have been presented for infection prevention and control (IPC) in the context of nursing homes.

An AHA scientific statement explores how AI, mobile imaging, and telehealth support acute stroke triage and treatment decisions within virtual networks.

Use of MHT following menopause is not associated with an increased risk for breast cancer among BRCA1 and BRCA2 carriers.

The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.

New ACC/AHA guidelines provide updated management strategies for the growing population of adults living with congenital heart disease.

The FDA has approved an expanded indication for MED-EL cochlear implants for children ages 7 months and older with bilateral SNHL.

High triglyceride-glucose index levels are associated with increased probable dementia risk, though intensive BP targets may mitigate this relationship.

For adolescent and young adult breast cancer survivors, a scalable mobile health intervention improves QoL and reduces specific symptoms.

HRS/ACC statement guides expanded access for intracardiac ablation procedures in ambulatory surgical centers for appropriate patients.

The FDA has approved Waskyra (etuvetidigene autotemcel) as the first cell-based gene therapy for the treatment of WAS.